Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A team of medical research and statistical modelling experts at Oxford University and the Alan Turing Institute have conducted a joint analysis to assess the impact of the NHS COVID-19 contact tracing app.

Phone screen showing the app in use

The research suggests the app stopped between 200,000 and 900,000 infections between 1st October and 31st December 2020, when 1.9 million people were infected with coronavirus in England and Wales.

Christophe Fraser, Professor of Pathogen Dynamics at Oxford University’s Big Data Institute, Nuffield Department of Medicine, explains: 'We used two separate approaches to analyse the impact of the more than 1.5 million notifications sent by the app in 2020, and both showed that between 200,000 and 900,000 infections have been averted. The impact of the app could be increased if more people use it. For each 1% increase in users we estimate the number of cases will drop by between 0.8% and 2.3%.'

The report shows the app was downloaded onto over 21 million phones, out of 33.7 million eligible people with compatible smartphones living in England and Wales. In 2020, the app sent out an average of 4.4 quarantine notifications for each user who shared their positive test result though the app. Most alerts went out in the second half of December when cases were rising rapidly across the UK due to the new B117 variant.

Read the full story on the University of Oxford website.

The story is also featured in the Fraser Group Coronavirus blog.

Similar stories

Wellcome accolades for Dr Douglas

Dr Alexander (Sandy) Douglas, an investigator at the Jenner Institute, Nuffield Department of Medicine, has recently received two prestigious Wellcome accolades.

FOCUS4: a flagship trial in colorectal cancer

Professor Tim Maughan (Department of Oncology) outlines the flagship work of the FOCUS4 trials, whose results were presented last weekend at the European Society of Medical Oncology (ESMO) annual meeting

Oxford and Oracle partner to speed identification of COVID-19 variants

The fast spread of the highly infectious Delta variant underscores the need for faster identification of COVID-19 mutations. Uniting governments and medical communities in this challenge, the University of Oxford and Oracle’s Global Pathogen Analysis System (GPAS) is now being used by organizations on nearly every continent. Institutions using the platform include: the University of Montreal Hospital Centre Research Centre, the Institute of Public Health Research of Chile, the Oxford University Clinical Research Unit in Vietnam, the Institute of Clinical Pathology and Medical Research – New South Wales Pathology, and Oxford Nanopore Technologies. GPAS is also now part of the Public Health England New Variant Assessment Platform.

Vaccinated groups at highest risk of Covid-19 hospitalisation and death identified using new QCovid tool

Researchers from the University of Oxford have today reported on findings on the vaccinated people who are at greatest risk from severe Covid-19 leading to hospitalisation or death from 14 days post the second dose vaccination, when substantial immunity should be expected.

Com-COV vaccine mix-and-match study expands to 12-to-16-year-olds

Researchers running the University of Oxford-led Com-COV programme have launched a new study of COVID-19 vaccination schedules in young people aged 12 to 16.